Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc (NQ: BEAM )

26.40 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 22
Open 26.40
Bid (Size) 26.10 (1)
Ask (Size) 27.00 (1)
Prev. Close 26.40
Today's Range 26.40 - 26.40
52wk Range 16.95 - 51.60
Shares Outstanding 79,199,501
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Lululemon To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach. 
Via The Motley Fool

Performance

YTD
-29.26%
-29.26%
1 Month
+19.13%
+19.13%
3 Month
+1.15%
+1.15%
6 Month
-19.95%
-19.95%
1 Year
-40.41%
-40.41%

More News

Read More
Cathie Wood's ARK Innovation ETF Achieves 35% Gain In November, Its Best Month Since Inception
Via Benzinga
Topics ETFs
The 3 Best Gene Editing Stocks on the Frontier of Medicine
Via InvestorPlace
Is Beam Therapeutics Stock a Buy Now?
Via The Motley Fool
Beam Therapeutics: Q3 Earnings Insights
Via Benzinga
Cathie Wood Loves This Beaten-Down Stock. But Is It in Trouble?
Via The Motley Fool
3 Monster Stocks in the Making
Via The Motley Fool
Right Now Could Be a Once-in-a-Generation Opportunity to Buy These Cathie Wood Stocks
Via The Motley Fool
Why Edible Garden Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners
Via Investor's Business Daily
2 Magnificent Growth Stocks That Might Be Badly Mispriced Right Now
Via The Motley Fool
Inside Cathie Wood’s Portfolio: 3 Stocks She Is Betting Millions On
Via InvestorPlace
Why Beam and Verve Therapeutics Shares Soared While Eli Lilly Soured Today
Via The Motley Fool
Verve Stock Soars On $250 Million Eli Lilly Deal
Via Investor's Business Daily
Arista Networks, JinkoSolar, Repligen, Shutterstock And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
After Cutting 20% of Its Staff, Is Beam Therapeutics Still a Buy?
Via The Motley Fool
Why Beam Therapeutics Stock Is Getting Bought Today
Via Benzinga
Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease
From Beam Therapeutics
Via GlobeNewswire
Cathie Wood's Ark Invest Scoops Up More Than $3M Worth Of SoFi Technologies Shares Amid Q3 Earnings Beat From Online Lender
Via Benzinga
Topics Earnings
Exposures Financial
5 Reasons Beam Therapeutics Remains a Risky Stock
Via The Motley Fool
Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT
From Beam Therapeutics
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.